Josua Jordi of Swiss biotech EraCal explains the company’s technology platform, their work with zebrafish larvae to find a biologic mechanism to control appetite, and how it compares with the new generation of obesity treatments coming from Big Pharma. Moreover, he discusses EraCal’s development strategy and the Swiss biotech ecosystem.
Zurich was a good fit for EraCal’s novel platform idea. There is more room for error here and the Swiss ecosystem truly has fantastic initiatives to push first-time entrepreneurs, not to mention the non-dilutive funding availability
